Prescription Medicines
Gabapen Cap.
- Product Category
- Powerful neuropathic pain/epilepsy treatment
- Active Ingredients
- Gabapentin
- Appearance
- Light yellow hard capsule containing white or off-white powder
- Reimbursement Code
- 648100010
01 / 02
1. Composition and Strength
Of 1 capsule
- Active ingredient: Gabapentin (USP)----300mg
- Additives (tar colorant): Yellow No. 5, Yellow No. 203
- Other additives: capsule, talc, povidone
2. Effectiveness
1. Epilepsy
1) Monotherapy (including treatment of patients newly diagnosed with seizures): Simple/complex partial seizures with or without secondary systemic symptoms in adolescents or adults over 13 years of age
2) Additional therapy: Partial seizures with or without secondary systemic symptoms in children or adults over 3 years of age.
2. Neuropathic pain
3. Dosage and dosage
1. Epilepsy
1) Monotherapy and adjunctive therapy for patients over 13 years of age
To achieve a maintenance dose of 900 mg/day as gabapentin, step titration is performed as follows over the first 3 days of administration.
- Day 1: Take 300 mg capsule of this drug once a day or 1 capsule of 100 mg of this drug 3 times a day (gabapentin 300 mg/day)
- Second day: Administer 300 mg capsules twice a day or 2 capsules 100 mg 3 times a day (gabapentin 600 mg/day)
- From the third day: Administer 300 mg capsules of this drug 3 times a day or 3 capsules of 100 mg of this drug 3 times a day (gabapentin 900 mg/day)
Alternatively, treatment may begin with one 300 mg capsule three times daily (gabapentin 900 mg/day). The dose may be increased to 1,200 mg/day of gabapentin, but the total daily dose must not exceed 2,400 mg. Safety and efficacy data for gabapentin doses above 2,400 mg/day are insufficient.
2) Additional therapy for children over 3 years old and under 12 years old
Stepwise titration to achieve a maintenance dose of 30 mg/day of gabapentin per kg of body weight is performed as follows over the first 3 days of administration.
- First day: 10 mg/kg of body weight (kg) administered as gabapentin
- Second day: 20 mg/kg of body weight (kg) administered as gabapentin
- From the third day: 30 mg/kg of body weight (kg) administered as gabapentin
If necessary, the dosage can be increased up to 40 mg per kg of body weight per day. When administering this drug, the total daily dose is divided into 3 doses.
2. Neuropathic pain
Adults (18 years of age or older): Step titration to maintain the maintenance dose of 900 mg/day as gabapentin is performed as follows over the first 3 days of administration.
- Day 1: Administer 300 mg capsule of this drug once a day or 1 capsule of 100 mg of this drug 3 times a day (gabapentin 300 mg/day)
- Second day: Administer 300 mg capsules of this drug twice a day or 2 capsules of 100 mg of this drug 3 times a day (gabapentin 600 mg/day)
- From the third day: Administer 300 mg capsules of this drug 3 times a day or 3 capsules of 100 mg of this drug 3 times a day (gabapentin 900 mg/day)
Alternatively, treatment may begin with one 300 mg capsule three times daily (gabapentin 900 mg/day).
If necessary, the dose can be increased to 1,800 mg/day as gabapentin within a week, and the total daily dose does not exceed 3,600 mg/day as gabapentin. When administering this drug, the total daily dose should be divided into three doses.
3. Weak patients: For weak patients with low body weight or patients after transplant surgery, the dose of gabapentin should be increased in 100 mg increments.
4. Elderly: Dose adjustment may be necessary due to decline in renal function due to aging (see table).
5. Patients with renal dysfunction (creatinine clearance less than 80 mL/min) or patients receiving hemodialysis: Dose adjustment is required based on the table below.
1) Dosage for patients with renal dysfunction:
※ Please check the attached document for details.
2) Capacity for hemodialysis patients
Initial dose: 300 to 400 mg of gabapentin is recommended.
Maintenance dose: 200 to 300 mg of gabapentin is administered after 4 hours of hemodialysis. This drug is not administered on days when hemodialysis is not performed.
6. Method and period of medication
1) This medicine must be swallowed whole with sufficient fluid, and can be administered alone or in combination with food. When administering three times a day, care must be taken to ensure that the interval between administrations does not exceed 12 hours to prevent recurrence of convulsions.
2) If the administration of this drug is missed (if more than 12 hours have passed since the last administration), the decision to administer an additional dose to make up for this should be decided at the discretion of the doctor.
3) When used together with antacids containing magnesium or aluminum, this drug should be administered at least 2 hours after the administration of the antacid. This can significantly reduce the decrease in bioavailability of this drug.
4) The period of administration of this drug should vary depending on clinical needs. Epilepsy treatment generally requires long-term administration. Although there is no evidence of a rebound phenomenon (increased frequency of epileptic seizures due to sudden discontinuation of treatment), sudden discontinuation of antiepileptic drugs in epilepsy patients may cause status epilepticus. If this drug must be discontinued or administered in combination with other antiepileptic drugs, the change should be made gradually for at least one week.
5) Safety and effectiveness over a period of administration of more than 5 months in the treatment of neuropathic pain have not been evaluated.
6) To reduce major side effects such as drowsiness, dizziness, fatigue, and ataxia, the first dose on the first day of administration should be administered at bedtime.
4. Precautions for use
1. Warning
1) Suicidal impulse and suicidal behavior
Because the risk of suicidal impulses or behavior increases in patients taking antiepileptic drugs, patients treated with antiepileptic drugs should be monitored for suicidal impulses or behavior, onset or worsening of depression, and abnormal changes in mood and behavior. Epilepsy and many other diseases for which antiepileptic drugs are prescribed are themselves associated with morbidity and mortality, and an increased risk of suicidal impulses and behavior during treatment. Therefore, when prescribing an antiepileptic drug, the prescriber considers the existence of a relationship between suicidal impulses or behavior during the patient's treatment period and the disease to be treated, as well as the effectiveness of the drug.
2) When medication is stopped, seizures and persistent epilepsy occur.
Antiepileptic drugs should not be taken suddenly because they have the potential to increase the frequency of seizures. In a placebo-controlled study, the incidence of persistent epilepsy in patients receiving this drug was 0.6% (3/543) and 0.5% (2/378) in patients receiving placebo. Through controlled and uncontrolled trials, 31 (1.5%) of 2,074 patients treated with this drug developed persistent epilepsy. Of these, 14 had no pre-symptoms of persistent epileptic status before treatment or during treatment with other medications. Due to the lack of adequate data, it cannot be said whether patients receiving this drug have a higher or lower incidence of seizures than patients not receiving this drug.
3) Carcinogenicity
In standard preclinical in vivo carcinogenicity studies, the incidence of pancreatic acinar adenocarcinoma was very high in male, but not female, rats (see Section 13. Other - Preclinical Data: Carcinogenicity, Mutagenicity, Fertility Disorders). The clinical significance of this is not yet known. There is no direct way to assess the drug's tumorigenic potential in humans in premarket clinical trials. In a clinical trial comparing 2,085 people, new tumors developed in 10 patients (2 breast cancers, 3 brain cancers, 2 lung cancers, 1 adrenal cancer, 1 non-Hodkin's lymphoma, 1 endometrial cancer), and in 11 cases, existing tumors worsened during the two years after stopping treatment with this drug. Without knowing the incidence in patients not treated with this drug, it is difficult to say whether this incidence is due to this drug or not.
4) Sudden and unexpected death
During the premarket development of this drug, 8 of the 2,203 administered patients (2,103 patients exposed for more than 1 year) died. Several of them were found to have died from epilepsy that was difficult to observe during the night. This represents a mortality rate of 0.0038 per patient-year. Although this rate is higher than the mortality rate in a healthy population for age and sex, it is within the estimated range of the incidence of sudden unexpected death in other epilepsy patients not receiving this drug (the incidence rate in all epilepsy patients is 0.0005, the incidence rate among patients in clinical trials similar to this drug is 0.003, and the incidence rate in patients with treatment-refractory epilepsy is 0.005). Ultimately, whether these numbers are confirmed or increased further depends on the reported patient population basis and the accuracy of the assessment.
5) Hemorrhagic pancreatitis has been reported in patients receiving this drug. Administration of this drug should be discontinued as soon as clinical signs of pancreatitis (persistent epigastric pain, nausea, recurrent vomiting) appear.
6) Neuropsychiatric adverse reactions - Pediatric patients between 3 and 12 years of age (limited to preparations that fall under “Children over 3 years of age” among the efficacy effects)
Administration of this drug to pediatric epilepsy patients aged 3 to 12 years is associated with the occurrence of adverse reactions related to the central nervous system. The most important adverse reactions can be classified as follows.
(1) Emotional instability (mainly behavioral abnormalities)
(2) Hostility (including aggressive behavior)
(3) Thinking abnormalities (concentration problems and changes in academic performance)
(4) Hyperactivity (mainly excessive activity without rest)
Most adverse reactions in patients receiving this drug were mild to moderate. In controlled clinical trials in pediatric patients aged 3 to 12 years, adverse reactions were emotional instability (6% in the gabapentin group, 1.3% in the control group), hostility (5.2%, 1.3%), hyperkinesis (4.7%, 2.9%), and abnormal thinking (1.7%, 0%). Among these, hostility was considered a serious adverse reaction. Treatment with this drug was discontinued in 1.3% of patients who reported emotional instability and hyperkinesis, and in 0.9% of patients who reported hostility and abnormal thinking. One patient receiving placebo discontinued the trial due to emotional instability.
7) Co-administration of this drug with central nervous system depressants, including narcotics (opioids), may cause deep sedation, respiratory depression, coma, and death. Because of these risks, co-administration of this drug and central nervous system depressants, including narcotics, should be prescribed only for patients for whom there are no appropriate alternative treatments.
If co-administration of this drug and a central nervous system depressant, including narcotics, is decided, prescribe it at the lowest effective dose for the shortest period of time and closely monitor the patient for signs and symptoms of respiratory depression and sedation (see ‘5. General precautions’ and ‘6. Interactions’).
2. Do not administer to the following patients.
1) Patients who have or have a history of hypersensitivity to this drug or its components
2) Patients with acute pancreatitis
3) Patients with generalized absence seizures or mixed seizures including these (not valid)
3. Administer with caution to the following patients (cases):
1) Patients with renal dysfunction
2) Elderly (age 65 or older)
3) Patients with a history of mental illness
4) Children with attention deficit disorder or behavioral disorders
5) Pregnant women, women who may be pregnant, or women who want to become pregnant
6) Nursing mothers
7) When administered to children and adolescents for more than 36 weeks
8) When administered for peripheral neuropathic pain for more than 5 months
4. Adverse reactions
1) Adverse reactions reported in clinical trials for ‘epilepsy’
As a result of evaluating the safety of this drug by administering it as an adjunctive therapy to more than 2,000 subjects and patients, it showed excellent tolerability. Of these, 543 patients participated in the controlled clinical trial. Because this drug was mostly administered in combination with other antiepileptic drugs, it is impossible to determine which drug the adverse reactions were related to. Additionally, this drug was evaluated as monotherapy in more than 600 patients, and adverse reactions were usually mild to moderate.
(1) Frequency of adverse reactions in controlled clinical trials administered as adjunctive therapy:
[Table 1] summarizes the adverse reactions that occurred in at least 1% of placebo-controlled clinical trials in which this drug was administered as an adjunct therapy to patients with partial seizures aged 13 years or older. In this trial, gabapentin and placebo were administered in addition to the antiepileptic drugs the patient was taking, and adverse reactions were usually mild to moderate.
[Table 1]※ Please check the attached document for details.
(2) Other adverse reactions observed in all clinical trials
① Additional therapy
In placebo-controlled clinical trials, it occurred in at least 1% of epilepsy patients who received gabapentin as adjunctive therapy. Adverse reactions not mentioned above are as follows.
- Whole body weakness, malaise, facial swelling
- Cardiovascular system: high blood pressure
- Digestive system: Flatulence, loss of appetite, gingivitis
- Blood and limb system: Purpura is mostly reported as a result of physical trauma.
- Musculoskeletal system: joint pain
- Nervous system: dizziness, hyperkinesis, increased, decreased or absent reflexes, paresthesia, anxiety, hostility
- Respiratory pneumonia
- Urinary system: urinary tract infection
- Special senses: Visual abnormalities mostly reported as visual impairment
② Monotherapy
No new or unexpected adverse reactions were reported in clinical trials using gabapentin as monotherapy. When comparing 300 mg/day and 3,600 mg/day, a dose-related relationship was observed, and the following adverse reactions occurred: dizziness, ataxia, drowsiness, paresthesia, and nystagmus.
③ Others
During all clinical trials, gabapentin was administered to 2,074 patients aged 13 years or older, only some of whom participated in placebo-controlled trials. All adverse reactions occurring in this clinical trial were recorded using terminology chosen by the clinical investigators. In order to meaningfully evaluate the rate of adverse reactions occurring in each individual, similar types of adverse reactions are grouped into a smaller number of standard categories using the COSTART dictionary terminology and listed below. The frequency expressed refers to the proportion of patients among 2,074 people exposed to this drug who experienced the adverse reactions mentioned below at least once while receiving this drug. All reported adverse reactions are included below, except those already listed above, those too general to be informative, and those that cannot reasonably be attributed to the use of the drug.
Frequently occurring adverse reactions occur in at least 1 in 100 people (1/100), infrequent adverse reactions occur in 1 in 100 to 1,000 people (1/100 to 1/1,000), and rare adverse reactions occur in less than 1 in 1,000 people.
- Full body:
-Frequent: Asthenia, malaise, facial swelling
- Occasionally: allergies, general swelling, weight loss, chills
-Rare: unfamiliar feeling, lethargy, alcohol intolerance, hangover effect
- Cardiovascular system:
- Frequently: high blood pressure
- Occasionally: hypotension, angina, peripheral vascular disorders, palpitations, tachycardia, migraine, murmur.
-Rare: atrial fibrillation, heart failure, thrombophlebitis, deep thrombophlebitis, myocardial infarction, cerebrovascular accident, pulmonary thrombosis, ventricular extrasystoles, bradycardia, immature atrial contraction, pericardial friction, heart block, pulmonary embolism, hyperlipidemia, hypercholesterolemia, pericardial effusion, pericarditis.
- Digestive system:
-Frequent: loss of appetite, flatulence, gingivitis
- Occasionally: glossitis, bleeding gums, thirst, stomatitis, increased salivation, gastroenteritis, hemorrhoids, bloody stool, fecal incontinence, hepatomegaly.
-Rare: Dysphagia, eructation, pancreatitis, gastric ulcer, colitis, intraoral blisters, tooth discoloration, angular stomatitis, salivary gland hypertrophy, lip bleeding, esophagitis, hiatal hernia, hematemesis, proctitis, irritable bowel syndrome, rectal bleeding, esophageal spasm.
- Endocrine system:
-Rare: hyperthyroidism, hypothyroidism, hyperthyroidism, hypoestrogens, ovarian failure, epididymitis, testicular swelling, cushingoid appearance.
- Blood and lymphatic system
-Frequent: purpuric spots that look like bruises due to trauma
- Occasionally: anemia, lymphadenopathy, thrombocytopenia
-Rare: increased white blood cell count, lymphocytosis, non-Hopkins lymphoma, increased bleeding time
- Musculoskeletal system:
-Frequent: joint pain
- Occasionally: tendonitis, arthritis, joint stiffness, joint swelling, positive Romberg test
-Rare: costochondritis, osteoporosis, pouchitis, contracture
- Nervous system:
-Frequent: Dizziness, hyperkinesis, paresthesia, decreased or lost reflexes, increased reflexes, anxiety, hostility.
- Occasionally: CNS tumor, syncope, dream abnormalities, aphasia, hypoesthesia, intracranial hemorrhage, hypotonia, paraesthesia, paresis, dystonia, hemiplegia, facial paralysis, stupor, cerebellar dysfunction, benign Babinski syndrome, decreased positional sense, subdural hematoma, apathy, hallucinations, decreased or loss of sexual desire, agitation, paranoia, depersonalization, strange situation hallucinations, feelings of intoxication. high), hallucination (doped-up sensation), suicidal impulse, insanity
-Rare: Chorea athetosis, perioral movement disorder, brain disease, nerve paralysis, personality disorder, increased libido, temperament inhibition, apraxia, fine motor control disorder, meningitis, focal myoclonus, hyperesthesia, dyskinesia, mania, neurosis, hysteria, antisocial reaction, suicidal behavior.
- Respiratory system:
-Frequent: Pneumonia
-Sometimes: nosebleeds, difficulty breathing, apnea
-Rare: Mucositis, aspiration pneumonia, hyperventilation, hiccups, laryngitis, nasal congestion, snoring, bronchospasm, hypoventilation, pulmonary edema.
- Skin:
- Occasionally: hair loss, eczema, dry skin, increased sweating, hives, male pattern hirsutism, seborrhea, cysts, herpes simplex
-Rare: Herpes zoster, skin discoloration, skin papules, photosensitivity, leg ulcers, scalp seborrhea, psoriasis, epidermal desquamation, maceration, cutaneous nodules, subcutaneous nodules, melanosis, skin necrosis, local swelling.
- Genitourinary system:
- Occasionally: hematuria, urinary dysfunction, frequent urination, cystitis, urinary retention, urinary incontinence, vaginal bleeding, amenorrhea, menstrual abnormalities, menorrhagia, breast cancer, athiasis, abnormal ejaculation
-Rare: kidney pain, white spots, genital itching, renal stones, acute renal failure, anuria, diabetes, nephritis, enuresis, pyuria, urinary urgency, vaginal pain, mastalgia, testicular pain.
- Special senses:
-Frequent: Vision abnormalities
- Occasionally: Cataracts, conjunctivitis, dry eyes, eye pain, photophobia, bilateral or unilateral ptosis, ocular hemorrhage, hordeorrhea, hearing loss, ear pain, tinnitus, otitis media, ear inflammation, loss of taste, dysgeusia, ocular twitching, ear fullness.
-Rare: eye itching, abnormal accommodation, perforation of the tympanic membrane, sensitivity to noise (hyperacusis), focal abnormality, galactorrhea, retinopathy, glaucoma, iritis, corneal disorders, lacrimal dysfunction, eye degeneration, blindness, retinal degeneration, miosis, chorioretinitis, strabismus, Eustachian tube dysfunction, otitis media, otitis externa, parosmia.
④ Administration to children (limited to preparations that fall under “Children over 3 years of age” among the efficacy effects)
The most common adverse reactions that occurred when this drug was administered in combination with other antiepileptic drugs to epilepsy patients aged 3 to 12 years and younger than 12 years old were viral infection, fever, nausea and/or vomiting, and drowsiness.
[Table 2] ※ Please check the attached document for details.
Other adverse reactions that occurred in more than 2% of pediatric patients and occurred at the same or greater frequency than the placebo treatment group are as follows. : Pharyngitis, upper respiratory tract infection, headache, rhinitis, cramps, diarrhea, loss of appetite, cough, otitis media
Adverse reactions not mentioned above that occurred during the clinical trial on 449 patients aged between 3 and 12 years of age are as follows.
- Whole body: dehydration, infectious mononuclear cell increase
- Digestive system: Hepatitis
- Blood and lymphatic system: Blood coagulation abnormalities
- Nervous system: loss of aura, occipital neuralgia
- Psychobiological function: sleepwalking
- Respiratory system: pseudocroup, hoarseness
(3) Discontinuation of administration due to adverse reactions
① Additional therapy
In clinical trials in which the drug was administered to more than 2,000 healthy volunteers and patients with epilepsy, convulsions, and migraines, approximately 7% discontinued treatment due to adverse reactions. In all clinical trials, the most frequent adverse reactions associated with discontinuation of this drug were drowsiness, ataxia, dizziness, fatigue, nausea, and/or vomiting. Almost all participants had multiple adverse events, none of which could be considered major.
② Monotherapy
In premarket clinical trials, approximately 8% of the 659 patients who received this drug as monotherapy or were switched to monotherapy discontinued treatment due to adverse reactions. The most common adverse reactions associated with discontinuation of treatment were dizziness, nervousness, weight gain, nausea and/or vomiting, and drowsiness.
③ Administration to children
In clinical trials, approximately 8% of 292 patients aged between 3 and 12 who received this drug discontinued treatment due to adverse reactions. The most common adverse reactions associated with discontinuation of treatment were drowsiness, hyperkinesia, and hostility.
2) Adverse reactions reported in clinical trials for neuropathic pain
(1) Adverse reactions that occurred in more than 1% of placebo-controlled clinical trials in which this drug was administered to patients with neuropathic pain are shown in [Table 3].
[Table 3] ※ Please check the attached document for details.
(2) Among the adverse reactions obtained from 1,173 patients in double-blind and open clinical trials, including some neuropathic pain conditions for which efficacy has not been established, the adverse reactions excluding those listed in the table above and those that cannot be considered related to the use of the drug are as follows.
Frequently occurring adverse reactions occur in at least 1 person per 100 people, occasionally occurring adverse reactions occur in 1 person per 100 to 1,000 people (1/100 to 1/1000), and rare adverse reactions occur in less than 1 person per 1,000 people.
- Full body:
- Occasionally: chest pain, cellulitis, malaise, neck pain, facial swelling, allergic reaction, abscess, chills, chills and fever, mucous membrane abnormalities
-Rare: body odor, cysts, fever, hernia, abnormal BUN level, cervical mass, pelvic pain, sepsis, viral infection.
- Cardiovascular system:
- Occasionally: hypertension, syncope, palpitations, migraine, hypotension, peripheral vascular disorder, cardiovascular disorder, cerebrovascular accident, congestive heart failure, myocardial infarction, vasodilatation
-Rare: angina pectoris, heart failure, increased capillary vulnerability, phlebitis, thrombophlebitis, varicose veins.
- Digestive system:
- Occasionally: gastroenteritis, increased appetite, gastrointestinal abnormalities, oral moniliasis, gastritis, tongue abnormalities, thirst, dental abnormalities, stool abnormalities, loss of appetite, abnormal liver function test values, periodontal abscess.
-Rare: cholecystitis, cholelithiasis, duodenal ulcer, fecal incontinence, increased gamma glutamyl transpeptidase, gingivitis, intestinal obstruction, intestinal ulcer, melena, oral ulcer, rectal abnormalities, rectal bleeding, stomatitis.
- Endocrine system:
-Sometimes: Diabetes
- Blood and lymphatic system:
- Occasionally: ecchymosis, anemia
-Rare: lymphadenopathy, lymphomatous reaction, decreased prothrombin.
- Metabolism and nutrition:
- Occasionally: edema, gout, hypoglycemia, weight loss
-Rare: increased alkaline phosphatase, diabetic ketoacidosis, increased lactic dehydrogenase
- Musculoskeletal system:
- Occasionally: Arthritis, joint pain, muscle pain, arthrosis, leg cramps, myasthenia gravis
-Rare: shinbone pain, joint disorders, tendon disorders
- Nervous system:
-Frequent: confusion, depression
-Sometimes: Dizziness, nervousness, paresthesia, insomnia, neuropathy, decreased libido, anxiety, depersonalization, decreased reflexes, speech disorder, dream abnormalities, dysarthria, emotional instability, nystagmus, stupor, perioral paresthesia, strange situation hallucination, hyperesthesia, dyskinesia, suicide attempt.
-Rare: Agitation, hypertonia, increased libido, dyskinesia, myoclonus, vestibular disorder
- Respiratory system:
- Occasionally: increased cough, bronchitis, rhinitis, sinusitis, pneumonia, asthma, lung abnormalities, epistaxis
-Rare: hemoptysis, degeneration
- Skin and appendages:
- Occasionally: itching, skin ulcers, dry skin, shingles, skin abnormalities, fungal dermatitis, boils, herpes simplex, psoriasis, sweating, hives, blistering rash.
-Rare: Acne, hair abnormalities, maculopapular rash, nail abnormalities, skin carcinoma, skin discoloration, skin thickening
- Special senses:
- Occasionally: Vision abnormalities, ear pain, eye abnormalities, loss of taste, hearing loss
-Rare: conjunctival hyperemia, diabetic retinopathy, eye pain, fundus microbleeds, retinal vein thrombosis, loss of taste
- Genitourinary system:
- Occasionally: urinary tract infection, urination disorder, impotence, urinary incontinence, vaginal moniliasis, mastalgia, menstrual abnormalities, polyuria, urinary retention.
-Rare: Cystitis, ejaculation abnormality, penile swelling, gynecomastia, enuresis, pyelonephritis, scrotal swelling, frequent urination, urgency, urinary abnormality.
3) Adverse reactions reported in post-marketing surveillance
It has not been established whether sudden death is related to treatment with this drug. Additionally, adverse reactions reported after marketing include increased blood creatine phosphatase, rhabdomyolysis, acute renal failure, allergic reactions including urticaria, hair loss, anaphylaxis, angioedema, hyperglycemia and hypoglycemia (mostly observed in diabetic patients), breast enlargement, chest pain, toxic epidermal necrolysis, drug rash accompanied by increased eosinophils and systemic symptoms (DRESS), elevated liver function tests (LFTs), Erythema multiforme, falls, generalized edema, gynecomastia, hallucinations, hepatitis, hypersensitivity including systemic reactions, hyponatremia, jaundice, loss of consciousness, movement abnormalities such as chorea athetosis, dyskinesia, dystonia, myoclonus, palpitations, pancreatitis, sexual dysfunction (including changes in libido, ejaculation disorder, and dysorgasmia), mucocutaneous ocular syndrome (Stevens-Johnson syndrome), Thrombocytopenia, tinnitus, urinary incontinence, etc.
Withdrawal symptoms were observed in some patients when gabapentin was discontinued after short- or long-term administration. The most frequently reported symptoms include anxiety, insomnia, nausea, pain, sweating, tremors, headache, depression, feeling abnormal, dizziness, and malaise.
4) Patients treated with antiepileptic drugs show suicidal impulses or behavior, onset or worsening of depression, and abnormal changes in mood and behavior. An analysis of 199 placebo-controlled clinical trials (monotherapy and adjunctive therapy) using 11 different antiepileptic drugs showed that patients taking antiepileptic drugs had approximately twice the risk of suicidal impulses or behavior compared to patients receiving placebo. During the 12-week treatment period, the incidence of suicidal behavior or suicidal impulses was 0.43% in 27,864 antiepileptic drug-treated patients and 0.24% in 16,029 placebo-treated patients. This means that one out of 530 patients treated showed suicidal thoughts or behavior. There were four suicides in patients treated with this drug and no suicides in patients treated with placebo. However, the number of suicides is too small to conclude a link between this drug and suicide. An increased risk of suicidal impulses or behavior due to taking antiepileptic drugs was observed in the first week of starting drug treatment and continued throughout the treatment period. Most clinical trials could not exceed 24 weeks and could not assess the risk of suicidal thoughts or behavior beyond 24 weeks. The risk of suicidal impulses or behavior was consistent across the 11 antiepileptic drugs analyzed. The increased risk for antiepileptic drugs with diverse mechanisms of action and range of use indicates that there is a risk for all antiepileptic drugs used for any efficacy. The risk did not differ depending on age (5-100 years) in the clinical trials analyzed.
5) As a result of analysis and evaluation of clue information based on adverse event reporting data after drug marketing (1989-June 2017), the newly confirmed adverse cases are as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
• Nervous system - tongue paralysis (temporary symptom)
5. General precautions
1) Inform patients and their guardians that antiepileptic drugs may increase the risk of developing or worsening signs and symptoms of depression, abnormal changes in mood and behavior, suicidal impulses, suicidal behavior, or self-harm impulses, so that if the patient develops these symptoms or behaviors, they can be reported immediately to a medical professional.
2) There are no signs of rebound seizures when taking this drug, but if an epilepsy patient suddenly stops taking antiepileptic drugs, it may cause status epilepticus (see directions and dosage).
3) Patients should be instructed to take this medication as prescribed. Administration of this drug has been associated with dizziness and drowsiness, which may increase the frequency of accidental injuries (falls). Additionally, confusion, loss of consciousness, and mental disorders have been reported in post-marketing surveillance. Therefore, patients should be advised to exercise caution until they become familiar with the potential effects of this drug. Additionally, patients should be informed that administration of this drug may result in decreased attention/concentration/reflex motor skills and other signs or symptoms of central nervous system depression. Therefore, taking into account the effects that adverse reactions may have on patients' mental or motor behavior, patients are advised to avoid driving or operating complex machinery until they have sufficient experience with this drug.
4) Concurrent use of central nervous system depressants, including narcotics (opioids): Concurrent use of narcotics may increase the concentration of gabapentin. Patients who require concomitant administration of this drug and central nervous system depressants, including narcotics, should be carefully observed for symptoms of central nervous system depression such as drowsiness, sedation, and respiratory depression, and the dosage of this drug or central nervous system depressants, including narcotics, should be appropriately reduced.
Be careful when prescribing this drug and narcotics together as there is a risk of central nervous system depression.
A population-based, observational, nested case-control study in drug users reported that combined prescription of this drug and narcotics was associated with an increased risk of narcotic-related death compared to narcotic prescription alone (adjusted odds ratio [aOR] 1.49, 95% CI 1.18-1.88, p<0.001). 5) For patients with impaired renal function, the dosage should be reduced.
6) Experience in patients with chronic pancreatitis has not yet been established.
7) Since administration of this drug may cause weight gain, be careful of obesity. If there are signs of obesity, take appropriate measures such as diet and exercise therapy. In particular, weight gain may occur due to increased dosage or long-term administration, so measure body weight regularly.
8) Because there is a possibility that disorders such as amblyopia, visual abnormalities, and double vision may occur due to the administration of this drug, caution should be taken during examination, including asking questions about eye disorders, and if any adverse reactions occur, take appropriate measures.
9) Severe skin adverse reactions (SCARs)
In patients taking antiepileptic drugs, including gabapentin, severe, life-threatening systemic hypersensitivity reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS) have been reported. When prescribing, the patient should be informed of symptoms and signs and the patient's skin reaction should be closely observed. When symptoms and signs suggestive of these reactions develop, gabapentin administration should be discontinued immediately and alternative treatments (if appropriate) should be considered. Before starting treatment with gabapentin, if the patient may develop rash or other symptoms or signs of hypersensitivity such as fever or lymphadenopathy, and if the patient develops a serious reaction such as SJS, TEN, or DRESS due to the use of gabapentin, gabapentin should not be re-administered to the patient.
10) Anaphylaxis and angioedema
This drug may cause anaphylaxis and angioedema. In reported cases, signs and symptoms included difficulty breathing, swelling of the lips/throat/tongue, and low blood pressure requiring emergency treatment. If patients experience signs and symptoms of anaphylaxis or angioedema, stop taking this medicine and consult a doctor immediately.
11) Abuse potential and dependence
Gabapentin can cause drug dependence, which can occur at therapeutic doses. Cases of abuse and dependence have been reported in post-marketing data. Patients with a history of chemical substance abuse should use gabapentin with caution as they may be at higher risk for gabapentin misuse and dependence. Before prescribing gabapentin, the patient's risk of abuse or dependence should be carefully assessed. As with other central nervous system-active drugs, carefully evaluate patients for a history of substance abuse and/or psychiatric disorders and observe for possible signs of gabapentin abuse or dependence symptoms (e.g., drug-seeking behavior, dose escalation, development of tolerance).
12) Withdrawal symptoms
Withdrawal symptoms were observed in some patients when gabapentin was discontinued after short- or long-term administration. Withdrawal symptoms may occur shortly after discontinuation of treatment (usually within 48 hours). The most frequently reported symptoms include anxiety, insomnia, nausea, pain, sweating, tremors, headache, depression, feeling abnormal, dizziness, and malaise.
6. Interaction
1) There have been spontaneous reports and literature case reports of respiratory depression, sedation, and death related to the co-administration of gabapentin and central nervous system depressants, including narcotics (opioids). Some of these reports evaluated the co-administration of gabapentin and narcotics in frail patients, the elderly, patients with severe underlying respiratory diseases, and patients taking polypharmacy or drug abuse as being of particular concern.
2) Morphine: In a study on healthy volunteers (n=12), 60 mg sustained-release morphine capsules were administered 2 hours before 600 mg gabapentin capsules. Compared to when this drug was administered alone, the average AUC of gabapentin increased by 44%, and this was associated with an increase in pain threshold (cold pressor test). The clinical significance of these changes has not been determined. In this study, when this drug was administered 2 hours after morphine administration, there was no effect on the pharmacokinetic parameters of morphine. The narcotic (opioid)-mediated adverse reactions observed when morphine and this drug were co-administered were not significantly different from those observed when morphine and placebo were co-administered. Interactions at other doses are unknown.
3) No interactions were observed between this drug and phenobarbital, phenytoin, valproic acid, or carbamazepine. The steady-state pharmacokinetics of gabapentin are similar in healthy subjects and epilepsy patients receiving the above antiepileptic drugs.
4) Co-administration of this drug with oral contraceptives containing norethindrone and/or ethinyl estradiol did not affect the steady-state pharmacokinetics of each component.
5) Co-administration of this drug with an aluminum-magnesium complex antacid reduces the bioavailability of gabapentin by approximately 20%. It is recommended to take this medication at least 2 hours after administering antacids.
6) Renal excretion of gabapentin is not changed by probenecid.
7) The slight decrease in renal excretion of gabapentin observed during co-administration with cimetidine is not considered clinically significant.
8) Abuse of alcohol or drugs that act on the central nervous system may worsen the central nervous system side effects of this drug.
9) When administered in combination with naproxen sodium, the absorption of gabapentin increases by 12% to 15%.
10) When co-administered with hydrocodone, the Cmax and AUC of hydrocodone are reduced in proportion to the dose of gabapentin (after administering 125 mg of gabapentin, the Cmax and AUC of hydrocodone were 3% and 4% lower, respectively, and after administering 500 mg of gabapentin, the Cmax and AUC of hydrocodone were lowered by 21% and 22%, respectively.) Hydrocodone increases the AUC value of gabapentin by 14%. The extent of interaction at different doses is not yet known.
7. Administration to pregnant and lactating women
1) If gabapentin is used in the first trimester of pregnancy (within the first 3 months of pregnancy), serious birth defects may occur in the fetus. Gabapentin is not used during pregnancy unless the benefits to the mother clearly outweigh the potential risks to the fetus. Women of childbearing potential should use effective contraception during gabapentin treatment.
This drug crosses the human placenta. In children of women receiving antiepileptic drugs, the risk of congenital malformations increases 2-3 times.
An observational study including more than 1700 pregnancies exposed to gabapentin was conducted based on data routinely collected from administrative and medical registries in Denmark, Finland, Norway, and Sweden. Our results did not suggest a significant increased risk of major congenital malformations, abnormal birth outcomes, or abnormal postnatal neurodevelopmental outcomes with gabapentin exposure during pregnancy.
For major congenital malformations, the adjusted prevalence ratios (aPRs) and 95% confidence interval (CI) in a standard meta-analysis of groups exposed to gabapentin and those not exposed to antiepileptic drugs in the first trimester (within the first 3 months of pregnancy) were 0.99 (0.80-1.23).
Overall, there were no statistically significant findings for stillbirth, small for gestational age (SGA), low Apgar score, or microcephaly. aPR for low birth weight and preterm birth was 1.21 (1.02-1.44) and 1.16 (1.00-1.35).
This study showed no evidence of an increased risk of neurodevelopmental outcomes such as attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and intellectual disability in the pediatric population exposed in utero.
Neonatal withdrawal syndrome has been reported in neonates exposed to gabapentin in utero. Simultaneous exposure to gabapentin and narcotics during pregnancy may increase the risk of neonatal abstinence syndrome.
Animal tests showed reproductive toxicity. (See 13. Other preclinical data: Teratogenesis). The risk to humans is unknown. This drug should be administered only when the potential benefit to the pregnant woman is judged to outweigh the potential risk to the fetus.
2) Gabapentin is secreted into breast milk. Because the effect on breastfeeding infants is unknown, particular caution should be exercised when administering this drug to nursing mothers. This drug should be administered to nursing mothers only when the benefits outweigh the risks, and do not breast-feed when taking this drug.
3) There was no effect on reproductive performance in animal tests (see 13. Other - preclinical data: abnormalities in reproductive ability).
8. Administration to children
1) Safety and effectiveness in children under 3 years of age have not been established.
2) There is not sufficient experience with this drug as monotherapy in children under 13 years of age.
9. Administration to elderly people
The types of adverse reactions reported in 59 patients aged 65 years or older who took this drug in premarket clinical trials were not different from those reported in younger patients. In older patients, drowsiness, peripheral edema, and lethargy may occur more frequently. The dosage of this drug should be adjusted considering renal function (see Dosage and Administration).
10. Effect on clinical test values
When this drug is administered together with other antiepileptic drugs, false positive readings have been reported in the Ames N-Multistix SG dipstick test, so a more specific sulfosalicylic acid precipitation method is recommended for measuring urine protein.
11. Treatment in case of overdose
No acute, life-threatening toxicity was observed even at overdose doses of up to 49 g. Symptoms of overdose included dizziness, double vision, slurred speech, drowsiness, loss of consciousness, lethargy, coma, and mild diarrhea. All patients recovered sufficiently with supportive care. The phenomenon of decreased absorption of this drug at higher doses may limit drug absorption in case of overdose and thus minimize toxicity in case of overdose. However, overdosage of this drug in combination with other CNS depressants may result in coma. Although this drug can be removed by hemodialysis, previous experience has shown that hemodialysis is generally not necessary. However, patients with severe renal failure may require hemodialysis. The oral lethal dose of this drug has not been confirmed in mice and rats administered 8,000 mg/kg. Symptoms of acute toxicity in animals included ataxia, dyspnea, ptosis, and decreased activity or agitation.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Removing medicines from their original container and storing them in another container may cause accidents due to misuse of medicines or cause a decrease in the quality of medicines, so store them in their original containers.
13. Others
1) Information for patients: For safe and effective use of this drug, patients should be instructed to follow the instructions below.
(1) You must inform your doctor of any prescription or non-prescription drugs, alcohol, drugs you are currently taking, or any drugs you plan to take while taking this drug.
(2) If you are pregnant or planning to become pregnant, or if you become pregnant while taking this medicine, you must inform your doctor.
(3) This drug is secreted into breast milk, and its effects on nursing infants are unknown. Women who are breastfeeding should inform their doctor of this fact (see 7. Administration to pregnant and lactating women).
(4) This drug may impair your ability to drive or operate hazardous machinery. Avoid driving or operating complex machinery until you have sufficient experience with this medicine.
(5) To prevent seizures due to reduced effectiveness, care must be taken not to exceed 12 hours between administrations when administering this drug.
2) Preclinical data
(1) Carcinogenicity: This drug was administered to mice at doses of 200, 600, and 2,000 mg/kg/day and to rats at doses of 250, 1,000, and 2,000 mg/kg/day for 2 years. A statistically significant increase in the incidence of pancreatic acinar adenocarcinoma and carcinoma was found only in male rats receiving the highest dose. The peak plasma drug concentration in rats at a concentration of 2,000 mg/kg/day was 10 times higher than the plasma concentration administered in humans at 3,600 mg/day. In male rats, pancreatic acinar adenocarcinoma was a low-grade malignant tumor that did not affect survival, did not metastasize to surrounding tissues, and was similar to that seen in the control group. The relationship between this pancreatic acinar adenocarcinoma in male rats and carcinogenicity in humans is not clear.
(2) Mutagenicity: Gabapentin has been proven to have no genotoxic potential. It was not mutagenic in standard laboratory methods using bacterial or mammalian cells. Gabapentin did not cause structural chromosomal abnormalities in mammalian cells in the laboratory or in vivo, and did not induce micronuclei formation in the bone marrow of hamsters.
(3) Abnormalities in fertility: No adverse reactions to the fetus or reproduction were observed in rats up to a dose of 2,000 mg/kg (approximately 5 times the maximum daily human dose based on mg/m2).
(4) Teratogenesis: When gabapentin was administered to mice, rats, and rabbits at 50, 30, and 25 times the maximum daily human dose of 3,600 mg, the frequency of teratogenicity did not increase compared to the control group (4, 5, and 8 times the daily human dose based on mg/m2). In rodents, it caused delayed ossification of the skull, spine, forepaws, and hindpaws, which is a phenomenon of fetal growth delay. This effect was seen in pregnant mice at oral doses of 1,000 to 3,000 mg/kg/day during the organogenesis period and in rats at doses of 500, 1,000, or 2,000 mg/kg/day prior to mating, during mating, and during pregnancy. This is a dose equivalent to approximately 1 to 5 times the maximum daily dose of the human body on a mg/m2 basis. On the other hand, no effect was observed when 500 mg/kg/day (about 1/2 of the daily human dose based on mg/m2) was administered to pregnant mice. Cases where hydroureterosis and hydronephrosis occurred at a higher incidence than the control group were at 2,000 mg/kg/day in the reproductive function and general reproductive toxicity study, at 1,500 mg/kg/day in the teratogenicity study, and at 500, 1,000, and 2,000 mg/kg/day in the perinatal lactation period study. The significance of these correlations is unknown, but they are associated with developmental delay. This dose is mg/m2, which is about 1-5 times the human dose of 3,600 mg. In a teratogenesis study in rabbits, an increase in fetal mortality after implantation was observed at doses of 60, 300, and 1,500 mg/kg/day during the organogenesis period. This dose is mg/m2, which is about 1/4 to 8 times the human dose of 3600 mg.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 capsules/bottle, 100 capsules/bottle
7. Period of use
36 months from date of manufacture
Of 1 capsule
- Active ingredient: Gabapentin (USP)----300mg
- Additives (tar colorant): Yellow No. 5, Yellow No. 203
- Other additives: capsule, talc, povidone
2. Effectiveness
1. Epilepsy
1) Monotherapy (including treatment of patients newly diagnosed with seizures): Simple/complex partial seizures with or without secondary systemic symptoms in adolescents or adults over 13 years of age
2) Additional therapy: Partial seizures with or without secondary systemic symptoms in children or adults over 3 years of age.
2. Neuropathic pain
3. Dosage and dosage
1. Epilepsy
1) Monotherapy and adjunctive therapy for patients over 13 years of age
To achieve a maintenance dose of 900 mg/day as gabapentin, step titration is performed as follows over the first 3 days of administration.
- Day 1: Take 300 mg capsule of this drug once a day or 1 capsule of 100 mg of this drug 3 times a day (gabapentin 300 mg/day)
- Second day: Administer 300 mg capsules twice a day or 2 capsules 100 mg 3 times a day (gabapentin 600 mg/day)
- From the third day: Administer 300 mg capsules of this drug 3 times a day or 3 capsules of 100 mg of this drug 3 times a day (gabapentin 900 mg/day)
Alternatively, treatment may begin with one 300 mg capsule three times daily (gabapentin 900 mg/day). The dose may be increased to 1,200 mg/day of gabapentin, but the total daily dose must not exceed 2,400 mg. Safety and efficacy data for gabapentin doses above 2,400 mg/day are insufficient.
2) Additional therapy for children over 3 years old and under 12 years old
Stepwise titration to achieve a maintenance dose of 30 mg/day of gabapentin per kg of body weight is performed as follows over the first 3 days of administration.
- First day: 10 mg/kg of body weight (kg) administered as gabapentin
- Second day: 20 mg/kg of body weight (kg) administered as gabapentin
- From the third day: 30 mg/kg of body weight (kg) administered as gabapentin
If necessary, the dosage can be increased up to 40 mg per kg of body weight per day. When administering this drug, the total daily dose is divided into 3 doses.
2. Neuropathic pain
Adults (18 years of age or older): Step titration to maintain the maintenance dose of 900 mg/day as gabapentin is performed as follows over the first 3 days of administration.
- Day 1: Administer 300 mg capsule of this drug once a day or 1 capsule of 100 mg of this drug 3 times a day (gabapentin 300 mg/day)
- Second day: Administer 300 mg capsules of this drug twice a day or 2 capsules of 100 mg of this drug 3 times a day (gabapentin 600 mg/day)
- From the third day: Administer 300 mg capsules of this drug 3 times a day or 3 capsules of 100 mg of this drug 3 times a day (gabapentin 900 mg/day)
Alternatively, treatment may begin with one 300 mg capsule three times daily (gabapentin 900 mg/day).
If necessary, the dose can be increased to 1,800 mg/day as gabapentin within a week, and the total daily dose does not exceed 3,600 mg/day as gabapentin. When administering this drug, the total daily dose should be divided into three doses.
3. Weak patients: For weak patients with low body weight or patients after transplant surgery, the dose of gabapentin should be increased in 100 mg increments.
4. Elderly: Dose adjustment may be necessary due to decline in renal function due to aging (see table).
5. Patients with renal dysfunction (creatinine clearance less than 80 mL/min) or patients receiving hemodialysis: Dose adjustment is required based on the table below.
1) Dosage for patients with renal dysfunction:
※ Please check the attached document for details.
2) Capacity for hemodialysis patients
Initial dose: 300 to 400 mg of gabapentin is recommended.
Maintenance dose: 200 to 300 mg of gabapentin is administered after 4 hours of hemodialysis. This drug is not administered on days when hemodialysis is not performed.
6. Method and period of medication
1) This medicine must be swallowed whole with sufficient fluid, and can be administered alone or in combination with food. When administering three times a day, care must be taken to ensure that the interval between administrations does not exceed 12 hours to prevent recurrence of convulsions.
2) If the administration of this drug is missed (if more than 12 hours have passed since the last administration), the decision to administer an additional dose to make up for this should be decided at the discretion of the doctor.
3) When used together with antacids containing magnesium or aluminum, this drug should be administered at least 2 hours after the administration of the antacid. This can significantly reduce the decrease in bioavailability of this drug.
4) The period of administration of this drug should vary depending on clinical needs. Epilepsy treatment generally requires long-term administration. Although there is no evidence of a rebound phenomenon (increased frequency of epileptic seizures due to sudden discontinuation of treatment), sudden discontinuation of antiepileptic drugs in epilepsy patients may cause status epilepticus. If this drug must be discontinued or administered in combination with other antiepileptic drugs, the change should be made gradually for at least one week.
5) Safety and effectiveness over a period of administration of more than 5 months in the treatment of neuropathic pain have not been evaluated.
6) To reduce major side effects such as drowsiness, dizziness, fatigue, and ataxia, the first dose on the first day of administration should be administered at bedtime.
4. Precautions for use
1. Warning
1) Suicidal impulse and suicidal behavior
Because the risk of suicidal impulses or behavior increases in patients taking antiepileptic drugs, patients treated with antiepileptic drugs should be monitored for suicidal impulses or behavior, onset or worsening of depression, and abnormal changes in mood and behavior. Epilepsy and many other diseases for which antiepileptic drugs are prescribed are themselves associated with morbidity and mortality, and an increased risk of suicidal impulses and behavior during treatment. Therefore, when prescribing an antiepileptic drug, the prescriber considers the existence of a relationship between suicidal impulses or behavior during the patient's treatment period and the disease to be treated, as well as the effectiveness of the drug.
2) When medication is stopped, seizures and persistent epilepsy occur.
Antiepileptic drugs should not be taken suddenly because they have the potential to increase the frequency of seizures. In a placebo-controlled study, the incidence of persistent epilepsy in patients receiving this drug was 0.6% (3/543) and 0.5% (2/378) in patients receiving placebo. Through controlled and uncontrolled trials, 31 (1.5%) of 2,074 patients treated with this drug developed persistent epilepsy. Of these, 14 had no pre-symptoms of persistent epileptic status before treatment or during treatment with other medications. Due to the lack of adequate data, it cannot be said whether patients receiving this drug have a higher or lower incidence of seizures than patients not receiving this drug.
3) Carcinogenicity
In standard preclinical in vivo carcinogenicity studies, the incidence of pancreatic acinar adenocarcinoma was very high in male, but not female, rats (see Section 13. Other - Preclinical Data: Carcinogenicity, Mutagenicity, Fertility Disorders). The clinical significance of this is not yet known. There is no direct way to assess the drug's tumorigenic potential in humans in premarket clinical trials. In a clinical trial comparing 2,085 people, new tumors developed in 10 patients (2 breast cancers, 3 brain cancers, 2 lung cancers, 1 adrenal cancer, 1 non-Hodkin's lymphoma, 1 endometrial cancer), and in 11 cases, existing tumors worsened during the two years after stopping treatment with this drug. Without knowing the incidence in patients not treated with this drug, it is difficult to say whether this incidence is due to this drug or not.
4) Sudden and unexpected death
During the premarket development of this drug, 8 of the 2,203 administered patients (2,103 patients exposed for more than 1 year) died. Several of them were found to have died from epilepsy that was difficult to observe during the night. This represents a mortality rate of 0.0038 per patient-year. Although this rate is higher than the mortality rate in a healthy population for age and sex, it is within the estimated range of the incidence of sudden unexpected death in other epilepsy patients not receiving this drug (the incidence rate in all epilepsy patients is 0.0005, the incidence rate among patients in clinical trials similar to this drug is 0.003, and the incidence rate in patients with treatment-refractory epilepsy is 0.005). Ultimately, whether these numbers are confirmed or increased further depends on the reported patient population basis and the accuracy of the assessment.
5) Hemorrhagic pancreatitis has been reported in patients receiving this drug. Administration of this drug should be discontinued as soon as clinical signs of pancreatitis (persistent epigastric pain, nausea, recurrent vomiting) appear.
6) Neuropsychiatric adverse reactions - Pediatric patients between 3 and 12 years of age (limited to preparations that fall under “Children over 3 years of age” among the efficacy effects)
Administration of this drug to pediatric epilepsy patients aged 3 to 12 years is associated with the occurrence of adverse reactions related to the central nervous system. The most important adverse reactions can be classified as follows.
(1) Emotional instability (mainly behavioral abnormalities)
(2) Hostility (including aggressive behavior)
(3) Thinking abnormalities (concentration problems and changes in academic performance)
(4) Hyperactivity (mainly excessive activity without rest)
Most adverse reactions in patients receiving this drug were mild to moderate. In controlled clinical trials in pediatric patients aged 3 to 12 years, adverse reactions were emotional instability (6% in the gabapentin group, 1.3% in the control group), hostility (5.2%, 1.3%), hyperkinesis (4.7%, 2.9%), and abnormal thinking (1.7%, 0%). Among these, hostility was considered a serious adverse reaction. Treatment with this drug was discontinued in 1.3% of patients who reported emotional instability and hyperkinesis, and in 0.9% of patients who reported hostility and abnormal thinking. One patient receiving placebo discontinued the trial due to emotional instability.
7) Co-administration of this drug with central nervous system depressants, including narcotics (opioids), may cause deep sedation, respiratory depression, coma, and death. Because of these risks, co-administration of this drug and central nervous system depressants, including narcotics, should be prescribed only for patients for whom there are no appropriate alternative treatments.
If co-administration of this drug and a central nervous system depressant, including narcotics, is decided, prescribe it at the lowest effective dose for the shortest period of time and closely monitor the patient for signs and symptoms of respiratory depression and sedation (see ‘5. General precautions’ and ‘6. Interactions’).
2. Do not administer to the following patients.
1) Patients who have or have a history of hypersensitivity to this drug or its components
2) Patients with acute pancreatitis
3) Patients with generalized absence seizures or mixed seizures including these (not valid)
3. Administer with caution to the following patients (cases):
1) Patients with renal dysfunction
2) Elderly (age 65 or older)
3) Patients with a history of mental illness
4) Children with attention deficit disorder or behavioral disorders
5) Pregnant women, women who may be pregnant, or women who want to become pregnant
6) Nursing mothers
7) When administered to children and adolescents for more than 36 weeks
8) When administered for peripheral neuropathic pain for more than 5 months
4. Adverse reactions
1) Adverse reactions reported in clinical trials for ‘epilepsy’
As a result of evaluating the safety of this drug by administering it as an adjunctive therapy to more than 2,000 subjects and patients, it showed excellent tolerability. Of these, 543 patients participated in the controlled clinical trial. Because this drug was mostly administered in combination with other antiepileptic drugs, it is impossible to determine which drug the adverse reactions were related to. Additionally, this drug was evaluated as monotherapy in more than 600 patients, and adverse reactions were usually mild to moderate.
(1) Frequency of adverse reactions in controlled clinical trials administered as adjunctive therapy:
[Table 1] summarizes the adverse reactions that occurred in at least 1% of placebo-controlled clinical trials in which this drug was administered as an adjunct therapy to patients with partial seizures aged 13 years or older. In this trial, gabapentin and placebo were administered in addition to the antiepileptic drugs the patient was taking, and adverse reactions were usually mild to moderate.
[Table 1]※ Please check the attached document for details.
(2) Other adverse reactions observed in all clinical trials
① Additional therapy
In placebo-controlled clinical trials, it occurred in at least 1% of epilepsy patients who received gabapentin as adjunctive therapy. Adverse reactions not mentioned above are as follows.
- Whole body weakness, malaise, facial swelling
- Cardiovascular system: high blood pressure
- Digestive system: Flatulence, loss of appetite, gingivitis
- Blood and limb system: Purpura is mostly reported as a result of physical trauma.
- Musculoskeletal system: joint pain
- Nervous system: dizziness, hyperkinesis, increased, decreased or absent reflexes, paresthesia, anxiety, hostility
- Respiratory pneumonia
- Urinary system: urinary tract infection
- Special senses: Visual abnormalities mostly reported as visual impairment
② Monotherapy
No new or unexpected adverse reactions were reported in clinical trials using gabapentin as monotherapy. When comparing 300 mg/day and 3,600 mg/day, a dose-related relationship was observed, and the following adverse reactions occurred: dizziness, ataxia, drowsiness, paresthesia, and nystagmus.
③ Others
During all clinical trials, gabapentin was administered to 2,074 patients aged 13 years or older, only some of whom participated in placebo-controlled trials. All adverse reactions occurring in this clinical trial were recorded using terminology chosen by the clinical investigators. In order to meaningfully evaluate the rate of adverse reactions occurring in each individual, similar types of adverse reactions are grouped into a smaller number of standard categories using the COSTART dictionary terminology and listed below. The frequency expressed refers to the proportion of patients among 2,074 people exposed to this drug who experienced the adverse reactions mentioned below at least once while receiving this drug. All reported adverse reactions are included below, except those already listed above, those too general to be informative, and those that cannot reasonably be attributed to the use of the drug.
Frequently occurring adverse reactions occur in at least 1 in 100 people (1/100), infrequent adverse reactions occur in 1 in 100 to 1,000 people (1/100 to 1/1,000), and rare adverse reactions occur in less than 1 in 1,000 people.
- Full body:
-Frequent: Asthenia, malaise, facial swelling
- Occasionally: allergies, general swelling, weight loss, chills
-Rare: unfamiliar feeling, lethargy, alcohol intolerance, hangover effect
- Cardiovascular system:
- Frequently: high blood pressure
- Occasionally: hypotension, angina, peripheral vascular disorders, palpitations, tachycardia, migraine, murmur.
-Rare: atrial fibrillation, heart failure, thrombophlebitis, deep thrombophlebitis, myocardial infarction, cerebrovascular accident, pulmonary thrombosis, ventricular extrasystoles, bradycardia, immature atrial contraction, pericardial friction, heart block, pulmonary embolism, hyperlipidemia, hypercholesterolemia, pericardial effusion, pericarditis.
- Digestive system:
-Frequent: loss of appetite, flatulence, gingivitis
- Occasionally: glossitis, bleeding gums, thirst, stomatitis, increased salivation, gastroenteritis, hemorrhoids, bloody stool, fecal incontinence, hepatomegaly.
-Rare: Dysphagia, eructation, pancreatitis, gastric ulcer, colitis, intraoral blisters, tooth discoloration, angular stomatitis, salivary gland hypertrophy, lip bleeding, esophagitis, hiatal hernia, hematemesis, proctitis, irritable bowel syndrome, rectal bleeding, esophageal spasm.
- Endocrine system:
-Rare: hyperthyroidism, hypothyroidism, hyperthyroidism, hypoestrogens, ovarian failure, epididymitis, testicular swelling, cushingoid appearance.
- Blood and lymphatic system
-Frequent: purpuric spots that look like bruises due to trauma
- Occasionally: anemia, lymphadenopathy, thrombocytopenia
-Rare: increased white blood cell count, lymphocytosis, non-Hopkins lymphoma, increased bleeding time
- Musculoskeletal system:
-Frequent: joint pain
- Occasionally: tendonitis, arthritis, joint stiffness, joint swelling, positive Romberg test
-Rare: costochondritis, osteoporosis, pouchitis, contracture
- Nervous system:
-Frequent: Dizziness, hyperkinesis, paresthesia, decreased or lost reflexes, increased reflexes, anxiety, hostility.
- Occasionally: CNS tumor, syncope, dream abnormalities, aphasia, hypoesthesia, intracranial hemorrhage, hypotonia, paraesthesia, paresis, dystonia, hemiplegia, facial paralysis, stupor, cerebellar dysfunction, benign Babinski syndrome, decreased positional sense, subdural hematoma, apathy, hallucinations, decreased or loss of sexual desire, agitation, paranoia, depersonalization, strange situation hallucinations, feelings of intoxication. high), hallucination (doped-up sensation), suicidal impulse, insanity
-Rare: Chorea athetosis, perioral movement disorder, brain disease, nerve paralysis, personality disorder, increased libido, temperament inhibition, apraxia, fine motor control disorder, meningitis, focal myoclonus, hyperesthesia, dyskinesia, mania, neurosis, hysteria, antisocial reaction, suicidal behavior.
- Respiratory system:
-Frequent: Pneumonia
-Sometimes: nosebleeds, difficulty breathing, apnea
-Rare: Mucositis, aspiration pneumonia, hyperventilation, hiccups, laryngitis, nasal congestion, snoring, bronchospasm, hypoventilation, pulmonary edema.
- Skin:
- Occasionally: hair loss, eczema, dry skin, increased sweating, hives, male pattern hirsutism, seborrhea, cysts, herpes simplex
-Rare: Herpes zoster, skin discoloration, skin papules, photosensitivity, leg ulcers, scalp seborrhea, psoriasis, epidermal desquamation, maceration, cutaneous nodules, subcutaneous nodules, melanosis, skin necrosis, local swelling.
- Genitourinary system:
- Occasionally: hematuria, urinary dysfunction, frequent urination, cystitis, urinary retention, urinary incontinence, vaginal bleeding, amenorrhea, menstrual abnormalities, menorrhagia, breast cancer, athiasis, abnormal ejaculation
-Rare: kidney pain, white spots, genital itching, renal stones, acute renal failure, anuria, diabetes, nephritis, enuresis, pyuria, urinary urgency, vaginal pain, mastalgia, testicular pain.
- Special senses:
-Frequent: Vision abnormalities
- Occasionally: Cataracts, conjunctivitis, dry eyes, eye pain, photophobia, bilateral or unilateral ptosis, ocular hemorrhage, hordeorrhea, hearing loss, ear pain, tinnitus, otitis media, ear inflammation, loss of taste, dysgeusia, ocular twitching, ear fullness.
-Rare: eye itching, abnormal accommodation, perforation of the tympanic membrane, sensitivity to noise (hyperacusis), focal abnormality, galactorrhea, retinopathy, glaucoma, iritis, corneal disorders, lacrimal dysfunction, eye degeneration, blindness, retinal degeneration, miosis, chorioretinitis, strabismus, Eustachian tube dysfunction, otitis media, otitis externa, parosmia.
④ Administration to children (limited to preparations that fall under “Children over 3 years of age” among the efficacy effects)
The most common adverse reactions that occurred when this drug was administered in combination with other antiepileptic drugs to epilepsy patients aged 3 to 12 years and younger than 12 years old were viral infection, fever, nausea and/or vomiting, and drowsiness.
[Table 2] ※ Please check the attached document for details.
Other adverse reactions that occurred in more than 2% of pediatric patients and occurred at the same or greater frequency than the placebo treatment group are as follows. : Pharyngitis, upper respiratory tract infection, headache, rhinitis, cramps, diarrhea, loss of appetite, cough, otitis media
Adverse reactions not mentioned above that occurred during the clinical trial on 449 patients aged between 3 and 12 years of age are as follows.
- Whole body: dehydration, infectious mononuclear cell increase
- Digestive system: Hepatitis
- Blood and lymphatic system: Blood coagulation abnormalities
- Nervous system: loss of aura, occipital neuralgia
- Psychobiological function: sleepwalking
- Respiratory system: pseudocroup, hoarseness
(3) Discontinuation of administration due to adverse reactions
① Additional therapy
In clinical trials in which the drug was administered to more than 2,000 healthy volunteers and patients with epilepsy, convulsions, and migraines, approximately 7% discontinued treatment due to adverse reactions. In all clinical trials, the most frequent adverse reactions associated with discontinuation of this drug were drowsiness, ataxia, dizziness, fatigue, nausea, and/or vomiting. Almost all participants had multiple adverse events, none of which could be considered major.
② Monotherapy
In premarket clinical trials, approximately 8% of the 659 patients who received this drug as monotherapy or were switched to monotherapy discontinued treatment due to adverse reactions. The most common adverse reactions associated with discontinuation of treatment were dizziness, nervousness, weight gain, nausea and/or vomiting, and drowsiness.
③ Administration to children
In clinical trials, approximately 8% of 292 patients aged between 3 and 12 who received this drug discontinued treatment due to adverse reactions. The most common adverse reactions associated with discontinuation of treatment were drowsiness, hyperkinesia, and hostility.
2) Adverse reactions reported in clinical trials for neuropathic pain
(1) Adverse reactions that occurred in more than 1% of placebo-controlled clinical trials in which this drug was administered to patients with neuropathic pain are shown in [Table 3].
[Table 3] ※ Please check the attached document for details.
(2) Among the adverse reactions obtained from 1,173 patients in double-blind and open clinical trials, including some neuropathic pain conditions for which efficacy has not been established, the adverse reactions excluding those listed in the table above and those that cannot be considered related to the use of the drug are as follows.
Frequently occurring adverse reactions occur in at least 1 person per 100 people, occasionally occurring adverse reactions occur in 1 person per 100 to 1,000 people (1/100 to 1/1000), and rare adverse reactions occur in less than 1 person per 1,000 people.
- Full body:
- Occasionally: chest pain, cellulitis, malaise, neck pain, facial swelling, allergic reaction, abscess, chills, chills and fever, mucous membrane abnormalities
-Rare: body odor, cysts, fever, hernia, abnormal BUN level, cervical mass, pelvic pain, sepsis, viral infection.
- Cardiovascular system:
- Occasionally: hypertension, syncope, palpitations, migraine, hypotension, peripheral vascular disorder, cardiovascular disorder, cerebrovascular accident, congestive heart failure, myocardial infarction, vasodilatation
-Rare: angina pectoris, heart failure, increased capillary vulnerability, phlebitis, thrombophlebitis, varicose veins.
- Digestive system:
- Occasionally: gastroenteritis, increased appetite, gastrointestinal abnormalities, oral moniliasis, gastritis, tongue abnormalities, thirst, dental abnormalities, stool abnormalities, loss of appetite, abnormal liver function test values, periodontal abscess.
-Rare: cholecystitis, cholelithiasis, duodenal ulcer, fecal incontinence, increased gamma glutamyl transpeptidase, gingivitis, intestinal obstruction, intestinal ulcer, melena, oral ulcer, rectal abnormalities, rectal bleeding, stomatitis.
- Endocrine system:
-Sometimes: Diabetes
- Blood and lymphatic system:
- Occasionally: ecchymosis, anemia
-Rare: lymphadenopathy, lymphomatous reaction, decreased prothrombin.
- Metabolism and nutrition:
- Occasionally: edema, gout, hypoglycemia, weight loss
-Rare: increased alkaline phosphatase, diabetic ketoacidosis, increased lactic dehydrogenase
- Musculoskeletal system:
- Occasionally: Arthritis, joint pain, muscle pain, arthrosis, leg cramps, myasthenia gravis
-Rare: shinbone pain, joint disorders, tendon disorders
- Nervous system:
-Frequent: confusion, depression
-Sometimes: Dizziness, nervousness, paresthesia, insomnia, neuropathy, decreased libido, anxiety, depersonalization, decreased reflexes, speech disorder, dream abnormalities, dysarthria, emotional instability, nystagmus, stupor, perioral paresthesia, strange situation hallucination, hyperesthesia, dyskinesia, suicide attempt.
-Rare: Agitation, hypertonia, increased libido, dyskinesia, myoclonus, vestibular disorder
- Respiratory system:
- Occasionally: increased cough, bronchitis, rhinitis, sinusitis, pneumonia, asthma, lung abnormalities, epistaxis
-Rare: hemoptysis, degeneration
- Skin and appendages:
- Occasionally: itching, skin ulcers, dry skin, shingles, skin abnormalities, fungal dermatitis, boils, herpes simplex, psoriasis, sweating, hives, blistering rash.
-Rare: Acne, hair abnormalities, maculopapular rash, nail abnormalities, skin carcinoma, skin discoloration, skin thickening
- Special senses:
- Occasionally: Vision abnormalities, ear pain, eye abnormalities, loss of taste, hearing loss
-Rare: conjunctival hyperemia, diabetic retinopathy, eye pain, fundus microbleeds, retinal vein thrombosis, loss of taste
- Genitourinary system:
- Occasionally: urinary tract infection, urination disorder, impotence, urinary incontinence, vaginal moniliasis, mastalgia, menstrual abnormalities, polyuria, urinary retention.
-Rare: Cystitis, ejaculation abnormality, penile swelling, gynecomastia, enuresis, pyelonephritis, scrotal swelling, frequent urination, urgency, urinary abnormality.
3) Adverse reactions reported in post-marketing surveillance
It has not been established whether sudden death is related to treatment with this drug. Additionally, adverse reactions reported after marketing include increased blood creatine phosphatase, rhabdomyolysis, acute renal failure, allergic reactions including urticaria, hair loss, anaphylaxis, angioedema, hyperglycemia and hypoglycemia (mostly observed in diabetic patients), breast enlargement, chest pain, toxic epidermal necrolysis, drug rash accompanied by increased eosinophils and systemic symptoms (DRESS), elevated liver function tests (LFTs), Erythema multiforme, falls, generalized edema, gynecomastia, hallucinations, hepatitis, hypersensitivity including systemic reactions, hyponatremia, jaundice, loss of consciousness, movement abnormalities such as chorea athetosis, dyskinesia, dystonia, myoclonus, palpitations, pancreatitis, sexual dysfunction (including changes in libido, ejaculation disorder, and dysorgasmia), mucocutaneous ocular syndrome (Stevens-Johnson syndrome), Thrombocytopenia, tinnitus, urinary incontinence, etc.
Withdrawal symptoms were observed in some patients when gabapentin was discontinued after short- or long-term administration. The most frequently reported symptoms include anxiety, insomnia, nausea, pain, sweating, tremors, headache, depression, feeling abnormal, dizziness, and malaise.
4) Patients treated with antiepileptic drugs show suicidal impulses or behavior, onset or worsening of depression, and abnormal changes in mood and behavior. An analysis of 199 placebo-controlled clinical trials (monotherapy and adjunctive therapy) using 11 different antiepileptic drugs showed that patients taking antiepileptic drugs had approximately twice the risk of suicidal impulses or behavior compared to patients receiving placebo. During the 12-week treatment period, the incidence of suicidal behavior or suicidal impulses was 0.43% in 27,864 antiepileptic drug-treated patients and 0.24% in 16,029 placebo-treated patients. This means that one out of 530 patients treated showed suicidal thoughts or behavior. There were four suicides in patients treated with this drug and no suicides in patients treated with placebo. However, the number of suicides is too small to conclude a link between this drug and suicide. An increased risk of suicidal impulses or behavior due to taking antiepileptic drugs was observed in the first week of starting drug treatment and continued throughout the treatment period. Most clinical trials could not exceed 24 weeks and could not assess the risk of suicidal thoughts or behavior beyond 24 weeks. The risk of suicidal impulses or behavior was consistent across the 11 antiepileptic drugs analyzed. The increased risk for antiepileptic drugs with diverse mechanisms of action and range of use indicates that there is a risk for all antiepileptic drugs used for any efficacy. The risk did not differ depending on age (5-100 years) in the clinical trials analyzed.
5) As a result of analysis and evaluation of clue information based on adverse event reporting data after drug marketing (1989-June 2017), the newly confirmed adverse cases are as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
• Nervous system - tongue paralysis (temporary symptom)
5. General precautions
1) Inform patients and their guardians that antiepileptic drugs may increase the risk of developing or worsening signs and symptoms of depression, abnormal changes in mood and behavior, suicidal impulses, suicidal behavior, or self-harm impulses, so that if the patient develops these symptoms or behaviors, they can be reported immediately to a medical professional.
2) There are no signs of rebound seizures when taking this drug, but if an epilepsy patient suddenly stops taking antiepileptic drugs, it may cause status epilepticus (see directions and dosage).
3) Patients should be instructed to take this medication as prescribed. Administration of this drug has been associated with dizziness and drowsiness, which may increase the frequency of accidental injuries (falls). Additionally, confusion, loss of consciousness, and mental disorders have been reported in post-marketing surveillance. Therefore, patients should be advised to exercise caution until they become familiar with the potential effects of this drug. Additionally, patients should be informed that administration of this drug may result in decreased attention/concentration/reflex motor skills and other signs or symptoms of central nervous system depression. Therefore, taking into account the effects that adverse reactions may have on patients' mental or motor behavior, patients are advised to avoid driving or operating complex machinery until they have sufficient experience with this drug.
4) Concurrent use of central nervous system depressants, including narcotics (opioids): Concurrent use of narcotics may increase the concentration of gabapentin. Patients who require concomitant administration of this drug and central nervous system depressants, including narcotics, should be carefully observed for symptoms of central nervous system depression such as drowsiness, sedation, and respiratory depression, and the dosage of this drug or central nervous system depressants, including narcotics, should be appropriately reduced.
Be careful when prescribing this drug and narcotics together as there is a risk of central nervous system depression.
A population-based, observational, nested case-control study in drug users reported that combined prescription of this drug and narcotics was associated with an increased risk of narcotic-related death compared to narcotic prescription alone (adjusted odds ratio [aOR] 1.49, 95% CI 1.18-1.88, p<0.001). 5) For patients with impaired renal function, the dosage should be reduced.
6) Experience in patients with chronic pancreatitis has not yet been established.
7) Since administration of this drug may cause weight gain, be careful of obesity. If there are signs of obesity, take appropriate measures such as diet and exercise therapy. In particular, weight gain may occur due to increased dosage or long-term administration, so measure body weight regularly.
8) Because there is a possibility that disorders such as amblyopia, visual abnormalities, and double vision may occur due to the administration of this drug, caution should be taken during examination, including asking questions about eye disorders, and if any adverse reactions occur, take appropriate measures.
9) Severe skin adverse reactions (SCARs)
In patients taking antiepileptic drugs, including gabapentin, severe, life-threatening systemic hypersensitivity reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS) have been reported. When prescribing, the patient should be informed of symptoms and signs and the patient's skin reaction should be closely observed. When symptoms and signs suggestive of these reactions develop, gabapentin administration should be discontinued immediately and alternative treatments (if appropriate) should be considered. Before starting treatment with gabapentin, if the patient may develop rash or other symptoms or signs of hypersensitivity such as fever or lymphadenopathy, and if the patient develops a serious reaction such as SJS, TEN, or DRESS due to the use of gabapentin, gabapentin should not be re-administered to the patient.
10) Anaphylaxis and angioedema
This drug may cause anaphylaxis and angioedema. In reported cases, signs and symptoms included difficulty breathing, swelling of the lips/throat/tongue, and low blood pressure requiring emergency treatment. If patients experience signs and symptoms of anaphylaxis or angioedema, stop taking this medicine and consult a doctor immediately.
11) Abuse potential and dependence
Gabapentin can cause drug dependence, which can occur at therapeutic doses. Cases of abuse and dependence have been reported in post-marketing data. Patients with a history of chemical substance abuse should use gabapentin with caution as they may be at higher risk for gabapentin misuse and dependence. Before prescribing gabapentin, the patient's risk of abuse or dependence should be carefully assessed. As with other central nervous system-active drugs, carefully evaluate patients for a history of substance abuse and/or psychiatric disorders and observe for possible signs of gabapentin abuse or dependence symptoms (e.g., drug-seeking behavior, dose escalation, development of tolerance).
12) Withdrawal symptoms
Withdrawal symptoms were observed in some patients when gabapentin was discontinued after short- or long-term administration. Withdrawal symptoms may occur shortly after discontinuation of treatment (usually within 48 hours). The most frequently reported symptoms include anxiety, insomnia, nausea, pain, sweating, tremors, headache, depression, feeling abnormal, dizziness, and malaise.
6. Interaction
1) There have been spontaneous reports and literature case reports of respiratory depression, sedation, and death related to the co-administration of gabapentin and central nervous system depressants, including narcotics (opioids). Some of these reports evaluated the co-administration of gabapentin and narcotics in frail patients, the elderly, patients with severe underlying respiratory diseases, and patients taking polypharmacy or drug abuse as being of particular concern.
2) Morphine: In a study on healthy volunteers (n=12), 60 mg sustained-release morphine capsules were administered 2 hours before 600 mg gabapentin capsules. Compared to when this drug was administered alone, the average AUC of gabapentin increased by 44%, and this was associated with an increase in pain threshold (cold pressor test). The clinical significance of these changes has not been determined. In this study, when this drug was administered 2 hours after morphine administration, there was no effect on the pharmacokinetic parameters of morphine. The narcotic (opioid)-mediated adverse reactions observed when morphine and this drug were co-administered were not significantly different from those observed when morphine and placebo were co-administered. Interactions at other doses are unknown.
3) No interactions were observed between this drug and phenobarbital, phenytoin, valproic acid, or carbamazepine. The steady-state pharmacokinetics of gabapentin are similar in healthy subjects and epilepsy patients receiving the above antiepileptic drugs.
4) Co-administration of this drug with oral contraceptives containing norethindrone and/or ethinyl estradiol did not affect the steady-state pharmacokinetics of each component.
5) Co-administration of this drug with an aluminum-magnesium complex antacid reduces the bioavailability of gabapentin by approximately 20%. It is recommended to take this medication at least 2 hours after administering antacids.
6) Renal excretion of gabapentin is not changed by probenecid.
7) The slight decrease in renal excretion of gabapentin observed during co-administration with cimetidine is not considered clinically significant.
8) Abuse of alcohol or drugs that act on the central nervous system may worsen the central nervous system side effects of this drug.
9) When administered in combination with naproxen sodium, the absorption of gabapentin increases by 12% to 15%.
10) When co-administered with hydrocodone, the Cmax and AUC of hydrocodone are reduced in proportion to the dose of gabapentin (after administering 125 mg of gabapentin, the Cmax and AUC of hydrocodone were 3% and 4% lower, respectively, and after administering 500 mg of gabapentin, the Cmax and AUC of hydrocodone were lowered by 21% and 22%, respectively.) Hydrocodone increases the AUC value of gabapentin by 14%. The extent of interaction at different doses is not yet known.
7. Administration to pregnant and lactating women
1) If gabapentin is used in the first trimester of pregnancy (within the first 3 months of pregnancy), serious birth defects may occur in the fetus. Gabapentin is not used during pregnancy unless the benefits to the mother clearly outweigh the potential risks to the fetus. Women of childbearing potential should use effective contraception during gabapentin treatment.
This drug crosses the human placenta. In children of women receiving antiepileptic drugs, the risk of congenital malformations increases 2-3 times.
An observational study including more than 1700 pregnancies exposed to gabapentin was conducted based on data routinely collected from administrative and medical registries in Denmark, Finland, Norway, and Sweden. Our results did not suggest a significant increased risk of major congenital malformations, abnormal birth outcomes, or abnormal postnatal neurodevelopmental outcomes with gabapentin exposure during pregnancy.
For major congenital malformations, the adjusted prevalence ratios (aPRs) and 95% confidence interval (CI) in a standard meta-analysis of groups exposed to gabapentin and those not exposed to antiepileptic drugs in the first trimester (within the first 3 months of pregnancy) were 0.99 (0.80-1.23).
Overall, there were no statistically significant findings for stillbirth, small for gestational age (SGA), low Apgar score, or microcephaly. aPR for low birth weight and preterm birth was 1.21 (1.02-1.44) and 1.16 (1.00-1.35).
This study showed no evidence of an increased risk of neurodevelopmental outcomes such as attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and intellectual disability in the pediatric population exposed in utero.
Neonatal withdrawal syndrome has been reported in neonates exposed to gabapentin in utero. Simultaneous exposure to gabapentin and narcotics during pregnancy may increase the risk of neonatal abstinence syndrome.
Animal tests showed reproductive toxicity. (See 13. Other preclinical data: Teratogenesis). The risk to humans is unknown. This drug should be administered only when the potential benefit to the pregnant woman is judged to outweigh the potential risk to the fetus.
2) Gabapentin is secreted into breast milk. Because the effect on breastfeeding infants is unknown, particular caution should be exercised when administering this drug to nursing mothers. This drug should be administered to nursing mothers only when the benefits outweigh the risks, and do not breast-feed when taking this drug.
3) There was no effect on reproductive performance in animal tests (see 13. Other - preclinical data: abnormalities in reproductive ability).
8. Administration to children
1) Safety and effectiveness in children under 3 years of age have not been established.
2) There is not sufficient experience with this drug as monotherapy in children under 13 years of age.
9. Administration to elderly people
The types of adverse reactions reported in 59 patients aged 65 years or older who took this drug in premarket clinical trials were not different from those reported in younger patients. In older patients, drowsiness, peripheral edema, and lethargy may occur more frequently. The dosage of this drug should be adjusted considering renal function (see Dosage and Administration).
10. Effect on clinical test values
When this drug is administered together with other antiepileptic drugs, false positive readings have been reported in the Ames N-Multistix SG dipstick test, so a more specific sulfosalicylic acid precipitation method is recommended for measuring urine protein.
11. Treatment in case of overdose
No acute, life-threatening toxicity was observed even at overdose doses of up to 49 g. Symptoms of overdose included dizziness, double vision, slurred speech, drowsiness, loss of consciousness, lethargy, coma, and mild diarrhea. All patients recovered sufficiently with supportive care. The phenomenon of decreased absorption of this drug at higher doses may limit drug absorption in case of overdose and thus minimize toxicity in case of overdose. However, overdosage of this drug in combination with other CNS depressants may result in coma. Although this drug can be removed by hemodialysis, previous experience has shown that hemodialysis is generally not necessary. However, patients with severe renal failure may require hemodialysis. The oral lethal dose of this drug has not been confirmed in mice and rats administered 8,000 mg/kg. Symptoms of acute toxicity in animals included ataxia, dyspnea, ptosis, and decreased activity or agitation.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Removing medicines from their original container and storing them in another container may cause accidents due to misuse of medicines or cause a decrease in the quality of medicines, so store them in their original containers.
13. Others
1) Information for patients: For safe and effective use of this drug, patients should be instructed to follow the instructions below.
(1) You must inform your doctor of any prescription or non-prescription drugs, alcohol, drugs you are currently taking, or any drugs you plan to take while taking this drug.
(2) If you are pregnant or planning to become pregnant, or if you become pregnant while taking this medicine, you must inform your doctor.
(3) This drug is secreted into breast milk, and its effects on nursing infants are unknown. Women who are breastfeeding should inform their doctor of this fact (see 7. Administration to pregnant and lactating women).
(4) This drug may impair your ability to drive or operate hazardous machinery. Avoid driving or operating complex machinery until you have sufficient experience with this medicine.
(5) To prevent seizures due to reduced effectiveness, care must be taken not to exceed 12 hours between administrations when administering this drug.
2) Preclinical data
(1) Carcinogenicity: This drug was administered to mice at doses of 200, 600, and 2,000 mg/kg/day and to rats at doses of 250, 1,000, and 2,000 mg/kg/day for 2 years. A statistically significant increase in the incidence of pancreatic acinar adenocarcinoma and carcinoma was found only in male rats receiving the highest dose. The peak plasma drug concentration in rats at a concentration of 2,000 mg/kg/day was 10 times higher than the plasma concentration administered in humans at 3,600 mg/day. In male rats, pancreatic acinar adenocarcinoma was a low-grade malignant tumor that did not affect survival, did not metastasize to surrounding tissues, and was similar to that seen in the control group. The relationship between this pancreatic acinar adenocarcinoma in male rats and carcinogenicity in humans is not clear.
(2) Mutagenicity: Gabapentin has been proven to have no genotoxic potential. It was not mutagenic in standard laboratory methods using bacterial or mammalian cells. Gabapentin did not cause structural chromosomal abnormalities in mammalian cells in the laboratory or in vivo, and did not induce micronuclei formation in the bone marrow of hamsters.
(3) Abnormalities in fertility: No adverse reactions to the fetus or reproduction were observed in rats up to a dose of 2,000 mg/kg (approximately 5 times the maximum daily human dose based on mg/m2).
(4) Teratogenesis: When gabapentin was administered to mice, rats, and rabbits at 50, 30, and 25 times the maximum daily human dose of 3,600 mg, the frequency of teratogenicity did not increase compared to the control group (4, 5, and 8 times the daily human dose based on mg/m2). In rodents, it caused delayed ossification of the skull, spine, forepaws, and hindpaws, which is a phenomenon of fetal growth delay. This effect was seen in pregnant mice at oral doses of 1,000 to 3,000 mg/kg/day during the organogenesis period and in rats at doses of 500, 1,000, or 2,000 mg/kg/day prior to mating, during mating, and during pregnancy. This is a dose equivalent to approximately 1 to 5 times the maximum daily dose of the human body on a mg/m2 basis. On the other hand, no effect was observed when 500 mg/kg/day (about 1/2 of the daily human dose based on mg/m2) was administered to pregnant mice. Cases where hydroureterosis and hydronephrosis occurred at a higher incidence than the control group were at 2,000 mg/kg/day in the reproductive function and general reproductive toxicity study, at 1,500 mg/kg/day in the teratogenicity study, and at 500, 1,000, and 2,000 mg/kg/day in the perinatal lactation period study. The significance of these correlations is unknown, but they are associated with developmental delay. This dose is mg/m2, which is about 1-5 times the human dose of 3,600 mg. In a teratogenesis study in rabbits, an increase in fetal mortality after implantation was observed at doses of 60, 300, and 1,500 mg/kg/day during the organogenesis period. This dose is mg/m2, which is about 1/4 to 8 times the human dose of 3600 mg.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 capsules/bottle, 100 capsules/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 11items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 11 | Gabapen Cap. | Precautions for use | 2024.06.26 | 5. Gabapen capsule change order (draft) and change comparison table added.pdfFile under review |
| 10 | Gabapen Cap. | Indications, Dosage and Administration, and Precautions for Use | 2023.12.18 | Gabapentin single drug (capsule) unified adjustment (draft)_Change comparison table added.pdfFile under review |
| 9 | Gabapen Cap. | Precautions for use | 2023.03.16 | Precautions for use_Gabapen capsule (including change comparison table).pdfFile under review |
| 8 | Gabapen Cap. | Precautions for use | 2018.12.24 | PDF0042_200402344_Precautions for use (Gabapen capsule).pdf |
| 7 | Gabapen Cap. | Gabapen capsule (precautions for use) | 2017.06.12 | HWPGabapentin single tablet, capsule unified adjustment plan.hwp |
| 6 | Gabapen Cap. | Gabapen capsule (precautions for use) | 2015.02.16 | HWPGabapentin_Single drug capsule_Unification adjustment plan.hwp |
| 5 | Gabapen Cap. | Gabapen Capsule (effectiveness, dosage, instructions for use... | 2011.12.29 | HWPGabapen Capsule Effectiveness_Usage_Dosage_Precautions for use.hwp |
| 4 | Gabapen Cap. | Gabapen capsule (precautions for use) | 2011.10.28 | HWPGabapen capsule (precautions for use).hwp |
| 3 | Gabapen Cap. | Gabapen capsule (precautions for use) | 2009.09.07 | HWP9. Change order for permission (Gabapen Capsule) (2009. 09.07).hwp |
| 2 | Gabapen Cap. | Gabapen capsule (precautions for use) | 2009.01.29 | HWP9. Change order for permission (Gabapen Capsule) (2009.01.29).hwp |
| 1 | Gabapen Cap. | Gabapen capsule (precautions for use) | 2007.09.17 | HWP9. Change order for permission (Gabapen Capsule) (2007.09.17).hwp |